home > epc > summer 2019 > the changing face of clinical data
European Pharmaceutical Contractor

The Changing Face of Clinical Data

Data collection and analysis have always been central to the development of new clinical interventions such as drug treatments, diagnostics, and medical devices. While clinical data have always been collected and analysed, in recent years emerging methods and technologies for collection, analysing and utilising data, as well as the sheer quantity of data collected have been changing, driven by innovation and an evolving drug development landscape.

Clinical data can take many forms, but are essentially any information collected about an individual over the course of their admission and treatment in a medical setting. These data can range from their medical record information (such as age and medical history), the clinical interventions they undergo (such as blood tests, drugs prescribed, and surgical procedures), and the resulting outcomes following an intervention. These measures form the basis of any clinical trial that seeks to establish the efficacy or safety of a novel drug treatment, medical device, or diagnostic.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
About the author

Aiden Flynn is the Founder of Exploristics and has more than 20 years’ experience in drug discovery and clinical development. After seven years as a lecturer at University College London, UK, Aiden spent 10 years at GlaxoSmithKline as a Director of statistical support for biomarker studies across R&D. In recent years, he has worked closely with the FDA and EMEA to develop tools and guidelines that support the use of biomarkers in clinical studies. Since founding Exploristics in 2009, Aiden has attracted over 50% of the world’s top pharma companies as clients, as well as many biotechnology, device, and diagnostic companies.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India forhigh quality, low   cost pharma solutions, CPhI & P-MEC Indiais the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India’s pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement